AU2020235140B2 - Syncytial oncolytic herpes simplex mutants as potent cancer therapeutics - Google Patents

Syncytial oncolytic herpes simplex mutants as potent cancer therapeutics

Info

Publication number
AU2020235140B2
AU2020235140B2 AU2020235140A AU2020235140A AU2020235140B2 AU 2020235140 B2 AU2020235140 B2 AU 2020235140B2 AU 2020235140 A AU2020235140 A AU 2020235140A AU 2020235140 A AU2020235140 A AU 2020235140A AU 2020235140 B2 AU2020235140 B2 AU 2020235140B2
Authority
AU
Australia
Prior art keywords
hsv
cancer
cell
seq
natural
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020235140A
Other languages
English (en)
Other versions
AU2020235140A1 (en
Inventor
Kevin A. Cassady
Timothy P. CRIPE
Julia K. HALLEY
Pin-Yi Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nationwide Childrens Hospital Inc
Original Assignee
Nationwide Childrens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nationwide Childrens Hospital Inc filed Critical Nationwide Childrens Hospital Inc
Publication of AU2020235140A1 publication Critical patent/AU2020235140A1/en
Application granted granted Critical
Publication of AU2020235140B2 publication Critical patent/AU2020235140B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • C12N15/8695—Herpes simplex virus-based vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/00051—Methods of production or purification of viral material
    • C12N2710/00052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020235140A 2019-03-14 2020-03-13 Syncytial oncolytic herpes simplex mutants as potent cancer therapeutics Active AU2020235140B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962818577P 2019-03-14 2019-03-14
US62/818,577 2019-03-14
US201962932725P 2019-11-08 2019-11-08
US62/932,725 2019-11-08
PCT/US2020/022806 WO2020186238A1 (en) 2019-03-14 2020-03-13 Syncytial oncolytic herpes simplex mutants as potent cancer therapeutics

Publications (2)

Publication Number Publication Date
AU2020235140A1 AU2020235140A1 (en) 2021-09-30
AU2020235140B2 true AU2020235140B2 (en) 2026-03-26

Family

ID=72426047

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020235140A Active AU2020235140B2 (en) 2019-03-14 2020-03-13 Syncytial oncolytic herpes simplex mutants as potent cancer therapeutics

Country Status (11)

Country Link
US (1) US12480097B2 (https=)
EP (1) EP3937960A4 (https=)
JP (2) JP7671253B2 (https=)
KR (1) KR102933002B1 (https=)
CN (1) CN113710259B (https=)
AU (1) AU2020235140B2 (https=)
BR (1) BR112021017651A2 (https=)
CA (1) CA3132867A1 (https=)
IL (1) IL286142B2 (https=)
SG (1) SG11202109707VA (https=)
WO (1) WO2020186238A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120380154A (zh) * 2022-12-14 2025-07-25 Eg427公司 改良型单纯疱疹病毒1型

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009361A1 (en) * 1999-08-03 2001-02-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Recombinant hsv-1 and live viral vaccines
WO2005005637A2 (en) * 2003-05-09 2005-01-20 Medigene, Inc. Herpes simplex virus comprising a genetically modified glycoprotein d
US20180133269A1 (en) * 2015-05-04 2018-05-17 The Brigham And Women's Hospital, Inc. Oncolytic hsv1 vector and methods of use
WO2018161825A1 (zh) * 2017-03-09 2018-09-13 厦门大学 一种重组单纯疱疹病毒及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5639361B2 (ja) * 2006-09-08 2014-12-10 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｈｓｖ−１及びｈｓｖ−２ワクチン並びにその使用方法
JP6726824B2 (ja) * 2013-07-17 2020-07-22 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 効率的な遺伝子送達用途のための非毒性ｈｓｖベクター及びその製造のための補完細胞
US10596234B2 (en) 2016-10-28 2020-03-24 University Of Southern California Compositions and methods to inhibit viral replication

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009361A1 (en) * 1999-08-03 2001-02-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Recombinant hsv-1 and live viral vaccines
WO2005005637A2 (en) * 2003-05-09 2005-01-20 Medigene, Inc. Herpes simplex virus comprising a genetically modified glycoprotein d
US20180133269A1 (en) * 2015-05-04 2018-05-17 The Brigham And Women's Hospital, Inc. Oncolytic hsv1 vector and methods of use
WO2018161825A1 (zh) * 2017-03-09 2018-09-13 厦门大学 一种重组单纯疱疹病毒及其用途

Also Published As

Publication number Publication date
AU2020235140A1 (en) 2021-09-30
JP2025028186A (ja) 2025-02-28
CN113710259A (zh) 2021-11-26
JP7671253B2 (ja) 2025-05-01
KR102933002B1 (ko) 2026-03-04
CN113710259B (zh) 2024-12-31
JP2022524379A (ja) 2022-05-02
IL286142B2 (en) 2026-03-01
EP3937960A4 (en) 2023-03-29
IL286142B1 (en) 2025-11-01
EP3937960A1 (en) 2022-01-19
SG11202109707VA (en) 2021-10-28
KR20210139306A (ko) 2021-11-22
CA3132867A1 (en) 2020-09-17
WO2020186238A1 (en) 2020-09-17
BR112021017651A2 (pt) 2021-11-16
US12480097B2 (en) 2025-11-25
US20220154149A1 (en) 2022-05-19
IL286142A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
AU2019377141B2 (en) Enhanced systems for cell-mediated oncolytic viral therapy
CN110128550B (zh) 一种新型的同时阻断免疫检查点pd-l1和tigit的复制型溶瘤腺病毒和应用
KR102197374B1 (ko) 분열 촉진 인자 활성화 단백질 키나제 의존성 재조합 우두 바이러스(md-rvv) 및 이의 용도
CN114174520A (zh) 用于选择性基因调节的组合物和方法
CN109069668A (zh) 用于眼病的基因疗法
MX2014008045A (es) Un herpesvirus koi recombinante y vacuna para la prevencion de una enfermedad causada por herpesvirus koi.
US10806761B2 (en) Oncolytic HSV1 vector and methods of use
CN103074305B (zh) 重组水痘-带状疱疹病毒
Niu et al. Construction of the recombinant duck enteritis virus delivering capsid protein VP0 of the duck hepatitis A virus
JP2025028186A (ja) 強力ながん治療薬としての合胞体腫瘍溶解性単純ヘルペス変異体
CN107586759A (zh) 一种重组新城疫病毒的构建方法及应用
JP7387623B2 (ja) 標的タンパク質を安定して発現できる組換えウイルス
JPH04504357A (ja) ワクシニアベクター、ワクシニア遺伝子およびその発現産物
CN113559134B (zh) 一种用于肿瘤治疗的药物
CN110038124A (zh) 猪瘟-猪传染性胸膜肺炎二联亚单位的疫苗及其制备方法和应用
CN102827875B (zh) 表达小鼠神经生长因子的重组腺病毒及其制备方法
EP2460878B1 (en) Orf7 deficient varicella virus, vaccine comprising the virus and use thereof
RU2821999C2 (ru) Синцитиальные онколитические мутанты herpes simplex в качестве мощных терапевтических средств для лечения рака
Grant et al. Engineering cell lines for production of replication defective HSV‐1 gene therapy vectors
JP2004532007A (ja) 腫瘍抑制、腫瘍復帰変異、アポトーシス、および／またはウイルス耐性に関与する配列、ならびにそれらの医薬品としての使用方法
Shiau et al. A simple selection system for construction of recombinant gD-negative pseudorabies virus as a vaccine vector
CN101502659A (zh) Krüppel样转录因子4的新用途
CN121628895A (zh) 增强型特异性启动子及其应用
CN118389455A (zh) 一种表达荧光素酶和荧光蛋白的重组猫疱疹病毒的制备和应用
WO2025024460A2 (en) Methods and compositions for modulating aav infection